BLT benitec biopharma limited

Nasdaq signal, page-3

  1. 3,728 Posts.
    lightbulb Created with Sketch.  11
    The next CR will be the first since Nant's involvement and it will be interesting to see how the capital market responds. I was never a fan of the Nant deal - for reasons that I have explained many times - and, so far, the share market has been pretty lukewarm towards it. Incidentally, we have just had the first anniversary of the Nant second tranche @18.5c. Certainly Nant has access to capital but tying more capital to new shares will surely push their ownership beyond 50%? The restrictive nature of the Nant deal (must spend most of money on BB-401) may be off-putting to other financiers?

    As our capital dwindles and our capital leverage dwindles with it, I hope that existing shareholders don't get left on the shelf.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.